Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.
Gesynta Pharma has raised $27.3M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
Gesynta Pharma's investors include Innovestor, Amboy Street Ventures, Hadean Ventures, Industrifonden, Stephen Industries.
Gesynta Pharma is headquartered in Stockholm, Sweden.
Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.
Gesynta Pharma is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gesynta Pharma — Funding & Investors." VCBacked, January 20, 2025, https://www.vcbacked.co/company/gesynta-pharma. Accessed July 20, 2026.
VCBacked. (2025). Gesynta Pharma — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/gesynta-pharma
{{cite web |title=Gesynta Pharma — Funding & Investors |url=https://www.vcbacked.co/company/gesynta-pharma |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated